Takeaways: Sunshine Biopharma’s approval for generic rivaroxaban (Xarelto) adds a high-volume, key anticoagulant to its Canadian portfolio and pairs with its existing generic apixaban to create ...
Takeaways: Vimy Pharma’s filing could position it as a domestic, lower-cost semaglutide supplier in Canada, which supports affordability and national supply resilience. The broader market ...
Takeaways: IHEEZO gives Apotex a differentiated, in‑clinic anesthetic that strengthens its positioning with Canadian ophthalmologists and complements its anti‑inflammatory an...
Takeaways: HArmonyCa with Lidocaine positions Allergan Aesthetics to capture more of Canada’s growing demand for longer-lasting, non-surgical facial rejuvenation by offering both immediate ...
Takeaways: Gazyva’s reimbursement recommendation is a clear commercial win for Roche because it opens the door to public coverage in a high-need, specialty autoimmune market...
Takeaways Vertex’s suzetrigine filing is important because it could bring Canada its first new acute pain drug class in more than 20 years, which would give hospitals and payers a non-...
Takeaways Thyconvi gives BioSyent a differentiated way into Canadian endocrinology by offering the first liquid levothyroxine, so it can compete on convenience and dosing flexibility r...
Takeaways Apo‑Semaglutide should put real downward pressure on Ozempic pricing in Canada and accelerate a shift of volume from the originator to generics, especially in publicly funded and emplo...
The pharmaceutical industry is once again approaching a major patent cliff, with several blockbuster therapies set to lose exclusivity over the next few years. For many companies, these products have ...
Real world evidence (RWE) is rapidly reshaping how therapies are evaluated, approved, and commercialized within global healthcare systems, including Canadian Health. Derived from real world data such ...
